Truist raised the firm’s price target on National Health Investors (NHI) to $83 from $81 and keeps a Buy rating on the shares. The company’s Q3 same-store senior housing operating portfolio performance was not as strong as we expected, but fundamentals remain firmly at the company’s back and there appears to be a strong pipeline of accretive investment opportunities, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NHI:
- National Health Investors price target raised to $88 from $80 at KeyBanc
- National Health Investors price target raised to $85 from $80 at Wells Fargo
- National Health Investors price target raised to $90 from $88 at BofA
- NHI Earnings Call: Growth Amidst Challenges
- National Health Investors Reports Strong Q3 2025 Results